The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and ...

The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

The Phase 1a/b trial of ADRX-0405 is taking place at trial sites across the U.S., with first readouts expected in Q4 2025.

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...

The Swiss drug development company Windward Bio recently announced that it had officially launched with a $200 million Series ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and commercialization of Regenxbio’s gene therapies RGX-121 for the treatment of ...